The pathophysiology and treatment of hereditary tyrosinemia type 1

Seminars in Liver Disease

Volumn 21, Issue 4, 2001, Pages 563-571

  Grompe, M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Hepatocarcinoma therapy; Succinylacetone; Tyrosinemia

Indexed keywords

2 (2 NITRO 4 TRIFLUOROMETHYLBENZYOL) 1,3 CYCLOHEXANEDIONE; 4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; ACETOACETIC ACID; AMINO ACID; COMPLEMENTARY DNA; ENZYME INHIBITOR; FUMARIC ACID; FUMARYLACETOACETASE; HERBICIDE; MIKADO; PHENYLALANINE; SUCCINIC ACID; SUCCINYLACETONE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; AMINOACIDEMIA; ANIMAL MODEL; CELL TRANSPLANTATION; CHILD; CHROMOSOME 15Q; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; FETUS; GENETIC DISORDER; HUMAN; INFANT; KNOCKOUT MOUSE; LABORATORY DIAGNOSIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MOSAICISM; MOUSE; NEWBORN; NEWBORN SCREENING; NONHUMAN; PORPHYRIA; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TYROSINEMIA;

ANIMALS; HUMANS; INFANT, NEWBORN; MICE; TYROSINEMIAS;

EID: 0035196687     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-19035     Document Type: Review

References (85)

1. Hypertyrosinemia
2. A defect in the metabolism of aromatic amino acids in premature infants: The role of vitamin C
3. Hereditary tyrosinemia type I-an overview
4. Visceral pathology of hereditary tyrosinemia type I Am
5. Neurologic crises in hereditary tyrosinemia
6. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure
7. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean
8. Cloning and expression of the cDNA encoding human fumarylacetoacetae hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15
9. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity
10. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I
11. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I
12. First-trimester prenatal diagnosis of tyrosinemia type I by amniotic fluid succinylacetone determination
13. A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid
14. Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells
15. Hereditary tyrosinemia type I: Strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis
16. The human fumarylacetoacetase gene: Characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency
17. TaqI RFLP for the human fumarylacetoacetate hydrolase (FAH) gene
18. MspI RFLP in the human fumarylacetoacetate hydrolase (FAH) gene
19. Bg1II RFLP for the human fumarylacetoacetate hydrolase (FAH) gene
20. Screening for tyrosinaemia type I
21. A system of early screening for inborn errors of metabolism: Methods and results for hereditary tyrosinemia
22. Dietary treatment eliminates succinylacetone from the urine of a patient with ryrosinemia type I
23. Liver transplantation in type I tyrosinemia
24. Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma
25. Resolution of the clinical features of tyrosinemia following orthotopic liver transplantation for hepatoma
26. Inherited hepatic enzyme defects as candidates for liver-directed gene therapy
27. From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug
28. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
29. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
30. Sural nerve lesions in a case of hypertyrosinemia
31. Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement
32. Presentation of the data of the Italian registry for oculocutaneous tyrosinaemia
33. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect
34. Self-induced correction of the genetic defect in tyrosinemia type I
35. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes
36. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I
37. Enzymes involved in conversion of tyrosine to acetoacetate
38. Homogentisate metabolism: The isomerization of maleylacetoacetate by an enzyme which requires glutathione
39. Homogentisate oxidase of liver
40. Crystal structure and mechanism of a carbon-carbon bond hydrolase
41. Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor
42. On the enzymic defects in hereditary tyrosinemia
43. The nature of the defect in tyrosine metabolism in alkaptonuria
44. Richner-Hanhart syndrome (tyrosinaemia-II) (report of four cases without ocular involvement)
45. The Richner-Hanhart syndrome: Report of a case with associated tyrosinemia
46. Putative genetic deficiency of 4-hydroxyphenylpyruvic acid dioxygenase in mice: A murine model for hereditary tyrosinaemia type III
47. Tyrosinemia type III: Diagnosis and ten-year follow-up
48. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice
49. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors
50. A mouse model of renal tubular injury of tyrosinemia type 1: Development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice
51. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis
52. Deletions near the albino locus on chromosome 7 of the mouse affect the level of tyrosine aminotransferase mRNA
53. Genetic control of morphogenetic and biochemical differentiation: Lethal albino deletions in the mouse
54. Trans regulation of the phosphoenolpyruvate carboxykinase (GTP) gene, identified by deletions in chromosome 7 of the mouse
55. A lethal deletion on mouse chromosome 7 affects regulation of liver cell-specific functions: Posttranscriptional control of serum protein and transcriptional control of aldolase B synthesis
56. Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes
57. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents
58. Marked increases in hepatic NAD(P)H: Oxidoreductase gene transcription and mRNA levels correlated with a mouse chromosome 7 deletion
59. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis
60. Interaction between the Ah receptor and proteins binding to the AP-l-like electrophile response element (EpRE) during murine phase II [Ah] battery gene expression
61. Effects of succinylacetone on amino acid uptake in the rat kidney
62. Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles
63. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion
64. In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
65. Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver
66. Analysis of the albinolocus region of the mouse. Origin and viability
67. Molecular mapping of albino deletions associated with early embryonic lethality in the mouse
68. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice
69. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
70. Therapeutic trials in the murine model of hereditary tyrosinemia type I: A progress report
71. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I
72. Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I
73. In vivo selection of hepatocytes transduced with adeno-associated viral vectors
74. The repopulation potential of hepatocyte populations differing in size and prior mitotic expansion
75. Hepatic repopulation by adult murine pancreatic liver stem cells
76. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes
77. Liver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cells
78. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
79. Liver repopulation for the treatment of metabolic diseases
80. Principles of therapeutic liver repopulation
81. Fungal metabolic model for human type I hereditary tyrosinaemia
82. Molecular characterization of a gene encoding a homogentisate dioxygenase from Aspergillus nidulans and identification of its human and plant homologues
83. Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue
84. The incidence of alkaptonuria: A study in chemical individuality
85. The molecular basis of alkaptonuria